A new study reports that mice shed about 20% of their body weight and saw their breast cancer tumors decrease after getting ...

Researchers found that tirzepatide, a medication primarily used for treating type 2 diabetes and weight loss, reduced body ...

Metabolic hypogonadism, a condition marked by low testosterone levels and frequently seen in obese individuals, contributes ...

Tirzepatide may confer larger increases in testosterone levels among men with metabolic hypogonadism than testosterone ...

Men receiving tirzepatide showed greater reductions in body weight and waist circumference and improvements in erectile ...

Tirzepatide helps obese adults lose over 15% of body weight in 52 weeks—and retain much of it even six months after stopping ...

Tirzepatide improves outcomes in patients with obesity-related HFpEF regardless of the severity of their baseline BMI or fat ...

Key TakeawaysThe weight-loss drug tirzepatide reduced both body fat and tumor growth in obese mice with breast cancer. Tumor ...

Baseline BMI may play a significant role in improving exercise capacity, body weight and BP among patients with HF with ...

Eli Lilly's biggest growth driver, tirzepatide, will continue facing scrutiny from investors and analysts. The company's oral ...

Starting tirzepatide that September, she shed 5 to 10 pounds a month. By July 1, 2020, she'd lost nearly 60 pounds, giving her one of the best results seen from the drug.

An injection drug known as tirzepatide, already approved by the FDA for treating Type 2 diabetes, is likely to gain approval for weight loss treatment this year. Here's what to know.